A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Facet Biotech
• Collaborator: PDL BioPharma, Inc.
• Treatments: Visilizumab

Criteria

Inclusion Criteria:

• Males and females, 18 years of age or older.

• Diagnosis of UC verified by endoscopy within 60 months prior to consent.